NASDAQ:POAI Predictive Oncology (POAI) Stock Price, News & Analysis $0.97 -0.05 (-4.90%) As of 03:49 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesSEC FilingsShort InterestTrendsBuy This Stock About Predictive Oncology Stock (NASDAQ:POAI) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Predictive Oncology alerts:Sign Up Key Stats Today's Range$0.96▼$1.0250-Day Range$0.73▼$1.0252-Week Range$0.55▼$3.06Volume68,744 shsAverage Volume1.75 million shsMarket Capitalization$10.56 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingHold Company Overview Predictive Oncology, Inc. is a biotechnology company that leverages artificial intelligence and digital biology to support drug discovery and development in oncology. Its core business revolves around the application of machine learning algorithms to high-content cellular imaging, multi-omic profiling, and clinical response data. By integrating these diverse data streams, the company aims to generate predictive models that forecast the efficacy and toxicity of candidate therapeutics, thereby accelerating preclinical decision-making and reducing development timelines. The company’s primary offerings include its Phenomics platform, which combines automated microscopy with advanced image analysis to capture subtle phenotypic changes in cancer cells. This platform is complemented by proprietary data integration tools that correlate cellular phenotypes with genetic and molecular profiles. Predictive Oncology also provides custom assay development and contract research services to pharmaceutical and biotech partners seeking to validate drug mechanisms, optimize dosing regimens, or identify novel targets in oncology and related therapeutic areas. Headquartered in St. James, New York, Predictive Oncology serves a global customer base that includes large pharmaceutical companies, emerging biotechs, and academic research institutions. The company began trading on the Nasdaq Capital Market under the ticker POAI in December 2020. Its leadership team brings together expertise in computational biology, oncology research, and data science, positioning Predictive Oncology at the intersection of cutting-edge technology and translational cancer research.AI Generated. May Contain Errors. Read More Predictive Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks26th Percentile Overall ScorePOAI MarketRank™: Predictive Oncology scored higher than 26% of companies evaluated by MarketBeat, and ranked 855th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Predictive Oncology.Read more about Predictive Oncology's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Predictive Oncology are expected to grow in the coming year, from ($2.08) to ($0.13) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Predictive Oncology is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Predictive Oncology is -0.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Predictive Oncology's valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted1.03% of the float of Predictive Oncology has been sold short.Short Interest Ratio / Days to CoverPredictive Oncology has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Predictive Oncology has recently decreased by 54.38%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPredictive Oncology does not currently pay a dividend.Dividend GrowthPredictive Oncology does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.03% of the float of Predictive Oncology has been sold short.Short Interest Ratio / Days to CoverPredictive Oncology has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Predictive Oncology has recently decreased by 54.38%, indicating that investor sentiment is improving significantly. News and Social Media3.6 / 5News Sentiment1.45 News SentimentPredictive Oncology has a news sentiment score of 1.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Predictive Oncology this week, compared to 1 article on an average week.Search Interest5 people have searched for POAI on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Predictive Oncology insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.44% of the stock of Predictive Oncology is held by insiders.Percentage Held by InstitutionsOnly 9.04% of the stock of Predictive Oncology is held by institutions.Read more about Predictive Oncology's insider trading history. Receive POAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Predictive Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. POAI Stock News HeadlinesPredictive Oncology partners with nonprofit for AI-powered drug repurposing following difficult second quarterSeptember 7, 2025 | bizjournals.comPredictive Oncology, Every Cure announce strategic collaborationSeptember 4, 2025 | msn.comWarren Buffett Issues Cryptic Warning on U.S. DollarImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: "Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you." This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight.September 17 at 2:00 AM | Banyan Hill Publishing (Ad)Predictive Oncology and Every Cure Announce a Strategic Collaboration to Pursue Drug Repurposing for Cancer PatientsSeptember 4, 2025 | globenewswire.comPredictive Oncology Finalizes Stock Exchange Purchase AgreementAugust 25, 2025 | theglobeandmail.comPREDICTIVE ONCOLOGY INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Predictive Oncology Inc. - POAIAugust 19, 2025 | globenewswire.comPredictive Oncology Inc.: Predictive Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate UpdateAugust 15, 2025 | finanznachrichten.dePredictive Oncology reports Q2 EPS (22c) vs. (53c) last yearAugust 15, 2025 | msn.comSee More Headlines POAI Stock Analysis - Frequently Asked Questions How have POAI shares performed this year? Predictive Oncology's stock was trading at $0.82 at the beginning of 2025. Since then, POAI shares have increased by 20.1% and is now trading at $0.9850. How were Predictive Oncology's earnings last quarter? Predictive Oncology Inc. (NASDAQ:POAI) released its quarterly earnings results on Wednesday, August, 13th. The medical instruments supplier reported ($0.22) EPS for the quarter, missing the consensus estimate of ($0.09) by $0.13. The medical instruments supplier earned $0 million during the quarter, compared to analysts' expectations of $1.50 million. Predictive Oncology had a negative net margin of 587.31% and a negative trailing twelve-month return on equity of 722.01%. When did Predictive Oncology's stock split? Shares of Predictive Oncology reverse split on Monday, April 24th 2023.The 1-20 reverse split was announced on Monday, April 24th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, April 24th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Predictive Oncology? Shares of POAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Predictive Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Predictive Oncology investors own include Ford Motor (F), Wells Fargo & Company (WFC), Zomedica (ZOM), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Bank of America (BAC) and Wayfair (W). Company Calendar Last Earnings8/13/2025Today9/17/2025Next Earnings (Estimated)11/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MEDICAL INFO SYS Sub-IndustryMedical Equipment Current SymbolNASDAQ:POAI CIK1446159 Webwww.precisiontherapeutics.com Phone(651) 389-4800FaxN/AEmployees30Year Founded2002Profitability EPS (Trailing Twelve Months)($3.05) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$12.66 million Net Margins-587.31% Pretax Margin-546.76% Return on Equity-722.01% Return on Assets-167.23% Debt Debt-to-Equity RatioN/A Current Ratio0.32 Quick Ratio0.31 Sales & Book Value Annual Sales$1.62 million Price / Sales6.68 Cash FlowN/A Price / Cash FlowN/A Book Value($0.03) per share Price / Book-33.13Miscellaneous Outstanding Shares10,890,000Free Float10,518,000Market Cap$10.82 million OptionableNot Optionable Beta1.37 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:POAI) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Predictive Oncology Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Predictive Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.